ONCS News and Press, OncoSec Medical Incorporated From 01/27/21

OncoSec Medical ([[ONCS]] -0.4%) has dosed first subjects in Phase 1 trial evaluating its COVID-19 vaccine  candidate, CORVax12, that consists of TAVO (interleukin-12 plasmid), OnocSec's cancer immunotherapy candidate, and DNA-encodable stabil...

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein First-in-Class Combination Vaccine Using OncoSec's IL-12 DNA Plasmid-Based Cancer Immunotherapy wi...

OncoSec Medical Closes $42.0 Million Public Offering of Common Stock PR Newswire PENNINGTON, N.J. and SAN DIEGO , Jan. 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company fo...

OncoSec Medical (ONCS) has priced its public offering of ~7.7M common shares at $5.45/share, with expected gross proceeds of ~$42M. Net proceeds will be used for development and commercialization of product candidates; R&D activities; potential acquisitions and in-licensing; andother gene...

OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock PR Newswire PENNINGTON, N.J. and SAN DIEGO , Jan. 21, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnol...

OncoSec Medical (ONCS) slumped 6.9% in after-hours trade after announcing plans to offer and sell shares in an underwritten public offering.Actual size, offer terms not yet disclosed.Proceeds to be used for clinical, regulatory, manufacturing and, if and when approved, potentia...

OncoSec Medical Announces Proposed Public Offering of Common Stock PR Newswire PENNINGTON, N.J. and SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused o...

Sirtex Medical US Holdings announces an advancement in its strategic collaboration with OncoSec Medical (ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation ((EP)) gene delivery system.The update provides Sirtex with the option to a...

Sirtex Medical announces collaboration update with OncoSec Medical PR Newswire Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate TAVO™ for the treatment of advanced melanoma WOBURN, Mass. , Jan. 19, 2021 /PRNe...

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exerci...